Three kinds of drug-eluting bead transarterial chemoembolisation for treating patients with unresectable non-small cell lung cancer

doi:10.5306/wjco.v17.i4.118070

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

(19)

(107)

(0)

(15)

(491)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. Apr 24, 2026; 17(4): 118070
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.118070

Table 3 Treatment response and survival outcomes, n (%)

	DOX group	OXA group	GEM group	P value
Objective response rates
1 month	7 (14.9)	6 (20.7)	9 (19.1)	0.78
3 months	8 (21.1)	6 (30.0)	10 (23.8)	0.75
6 months	6 (17.6)	7 (33.3)	6 (17.1)	0.29
Disease control rates
1 month	42 (89.4)	21 (72.4)	36 (76.6)	0.13
3 months	26 (68.4)	14 (70.0)	29 (69.0)	0.99
6 months	14 (41.2)	12 (57.1)	15 (42.9)	0.47
Loss of follow up	0 (0.0)	1 (3.4)	1 (2.1)	1.00
Deaths	28 (59.6)	10 (34.5)	26 (55.3)	0.09
Median OS (months)	10.2	29.6^a	10.7	0.05
Median PFS (months)	6.8	9.9	7.2	0.31

^aP < 0.05 vs the doxorubicin and gemcitabine groups.

OS: Overall survival; PFS: Progression-free survival; DOX: Doxorubicin; OXA: Oxaliplatin; GEM: Gemcitabine.

Full Size Table

Citation: Yuan HF, Kuang DL, Jiao DC, Bi YH. Three kinds of drug-eluting bead transarterial chemoembolisation for treating patients with unresectable non-small cell lung cancer. World J Clin Oncol 2026; 17(4): 118070
URL: https://www.wjgnet.com/2218-4333/full/v17/i4/118070.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i4.118070

Yuan HF, Kuang DL, Jiao DC, Bi YH. Three kinds of drug-eluting bead transarterial chemoembolisation for treating patients with unresectable non-small cell lung cancer. World J Clin Oncol 2026; 17(4): 118070 [DOI: 10.5306/wjco.v17.i4.118070]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.